Key Points
- Syndax Pharmaceuticals CMO Nicholas A.J. Botwood sold 31,235 shares on June 12 at an average price of $18.14, totaling about $566,603. He also sold 34,280 shares the day before, reducing his ownership by 33.91%.
- The stock rose 1.9% and opened Friday at $18.25, but it remains below its 50-day and 200-day moving averages. The company has a market cap of $1.62 billion and a 1-year range of $8.59 to $25.59.
- Recent earnings topped EPS expectations, with Q1 EPS of -$0.48 versus analysts' estimate of -$0.59, though revenue came in below forecasts. Wall Street sentiment remains mostly positive, with a consensus Moderate Buy rating and average target price of $42.55.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) CMO Nicholas A.J. Botwood sold 31,235 shares of the business's stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $18.14, for a total value of $566,602.90. Following the completion of the sale, the chief marketing officer owned 60,885 shares of the company's stock, valued at approximately $1,104,453.90. This trade represents a 33.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Nicholas A.J. Botwood also recently made the following trade(s):
- On Thursday, June 11th, Nicholas A.J. Botwood sold 34,280 shares of Syndax Pharmaceuticals stock. The shares were sold at an average price of $18.00, for a total value of $617,040.00.
Syndax Pharmaceuticals Trading Up 1.9%
Shares of SNDX stock opened at $18.25 on Friday. The company has a current ratio of 5.47, a quick ratio of 5.06 and a debt-to-equity ratio of 8.26. The stock has a market cap of $1.62 billion, a P/E ratio of -6.54 and a beta of 0.38. The stock has a 50 day simple moving average of $21.06 and a 200 day simple moving average of $21.22. Syndax Pharmaceuticals, Inc. has a 1 year low of $8.59 and a 1 year high of $25.59.
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.11. The business had revenue of $64.86 million during the quarter, compared to analysts' expectations of $69.76 million. Syndax Pharmaceuticals had a negative return on equity of 256.65% and a negative net margin of 111.88%.The firm's revenue for the quarter was up 224.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.98) earnings per share. On average, research analysts predict that Syndax Pharmaceuticals, Inc. will post -1.66 earnings per share for the current fiscal year.
Institutional Trading of Syndax Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Larson Financial Group LLC grew its holdings in Syndax Pharmaceuticals by 192.2% during the 3rd quarter. Larson Financial Group LLC now owns 2,922 shares of the company's stock worth $45,000 after acquiring an additional 1,922 shares during the period. Quantbot Technologies LP acquired a new stake in Syndax Pharmaceuticals during the 3rd quarter worth about $53,000. Smartleaf Asset Management LLC grew its holdings in Syndax Pharmaceuticals by 2,698.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company's stock worth $55,000 after acquiring an additional 2,564 shares during the period. Lazard Asset Management LLC acquired a new stake in Syndax Pharmaceuticals during the 2nd quarter worth about $66,000. Finally, Tower Research Capital LLC TRC grew its holdings in Syndax Pharmaceuticals by 103.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company's stock worth $79,000 after acquiring an additional 4,308 shares during the period.
Analyst Upgrades and Downgrades
Several research analysts have commented on SNDX shares. Jefferies Financial Group restated a "buy" rating and set a $40.00 price objective (down from $48.00) on shares of Syndax Pharmaceuticals in a research report on Monday, March 30th. JPMorgan Chase & Co. boosted their price objective on shares of Syndax Pharmaceuticals from $33.00 to $45.00 and gave the company an "overweight" rating in a research report on Monday, March 9th. UBS Group restated a "buy" rating on shares of Syndax Pharmaceuticals in a research report on Friday. Weiss Ratings restated a "sell (d-)" rating on shares of Syndax Pharmaceuticals in a research report on Friday, March 27th. Finally, HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Syndax Pharmaceuticals in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $42.55.
Read Our Latest Report on Syndax Pharmaceuticals
About Syndax Pharmaceuticals
(
Get Free Report)
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax's research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.
The company's lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
